| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025746439 |
| P356 | DOI | 10.2165/00003495-200363240-00009 |
| P698 | PubMed publication ID | 14664658 |
| P50 | author | Gillian M Keating | Q62563919 |
| P2093 | author name string | Therese M Chapman | |
| P2860 | cites work | Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials | Q30725010 |
| Renal transplantation in adults | Q33709680 | ||
| Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression | Q33782774 | ||
| International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology | Q34354852 | ||
| Role of anti-interleukin-2 receptor antibodies in kidney transplantation | Q34403566 | ||
| Daclizumab: a review of its use in the management of organ transplantation | Q34437964 | ||
| Reducing adverse effects of immunosuppressive agents in kidney transplant recipients | Q34547749 | ||
| Prevention of transplant rejection: current treatment guidelines and future developments | Q40880337 | ||
| Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection | Q41155370 | ||
| Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts | Q42670216 | ||
| Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. | Q42679476 | ||
| A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients | Q42686317 | ||
| Absence of acute rejection using basiliximab with triple immunosuppression in cadaveric kidney recipients in first three months | Q43533456 | ||
| Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients | Q43551295 | ||
| Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3. | Q43552867 | ||
| An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation | Q43592410 | ||
| A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function | Q43634001 | ||
| Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen | Q43640092 | ||
| Economic analysis of basiliximab in renal transplantation | Q43660951 | ||
| Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients | Q43687549 | ||
| Basiliximab induction improves the outcome of renal transplants in children and adolescents. | Q43712111 | ||
| A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients | Q43768141 | ||
| Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients | Q43828434 | ||
| Simulect, calcineurin inhibitor, mycophenolate mofetil, and prednisone is more effective than OKT3, calcineurin inhibitor, hycophendate mofetil, and prednisone in African American kidney recipients in reducing acute rejections and prolonging graft s | Q43828439 | ||
| Simulect, Neoral, Cellcept, and prednisone in kidney recipients with delayed graft function: a prospective controlled study | Q43828689 | ||
| Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection | Q43843796 | ||
| Single centre experience with basiliximab in paediatric renal transplantation | Q43867643 | ||
| Experience with basiliximab in pediatric renal transplantation | Q43963045 | ||
| Efficacy and safety of basiliximab in pediatric renal transplantation | Q43963047 | ||
| Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation | Q44053836 | ||
| Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients | Q44101569 | ||
| Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients | Q44104890 | ||
| Basiliximab versus ATG/ALG induction in pediatric renal transplants: comparison of herpes virus profile and rejection rates | Q44120195 | ||
| Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients. | Q44215932 | ||
| Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors | Q44256933 | ||
| Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation | Q44289401 | ||
| Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil | Q44339726 | ||
| Cost evaluation of basiliximab treatment for renal transplant patients in Japan | Q44511821 | ||
| Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation | Q44537550 | ||
| Potential of daclizumab in solid organ transplantation | Q46157719 | ||
| Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. | Q46798906 | ||
| Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group | Q47887130 | ||
| A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. | Q52029967 | ||
| The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. | Q53307784 | ||
| The Banff 97 working classification of renal allograft pathology | Q59314413 | ||
| Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation | Q71063194 | ||
| Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation | Q71770419 | ||
| Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group | Q72995990 | ||
| A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation | Q73117695 | ||
| Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients | Q73176253 | ||
| Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group | Q73207716 | ||
| Simulect: redefining immunosuppressive strategies | Q73303719 | ||
| Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients | Q73337920 | ||
| Improved graft survival after renal transplantation in the United States, 1988 to 1996 | Q73502580 | ||
| Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients | Q74348272 | ||
| Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group | Q74602309 | ||
| Screening for basiliximab exposure-response relationships in renal allotransplantation | Q74613772 | ||
| Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors | Q74617283 | ||
| The IL2 pathway in clinical immunosuppression | Q77369524 | ||
| Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non-Japanese patients | Q77369641 | ||
| A single center experience with basiliximab induction therapy in renal transplantation | Q77369654 | ||
| Renal transplantation with Simulect (basiliximab) plus Sandimmune Neoral-based immunosuppression: a report of 41 cases in Taiwan | Q77369675 | ||
| Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction | Q77369688 | ||
| P433 | issue | 24 | |
| P304 | page(s) | 2803-2835 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Basiliximab: a review of its use as induction therapy in renal transplantation. | |
| P478 | volume | 63 |
| Q47193453 | Analysis of Risk Factors for Kidney Retransplant Outcomes Associated with Common Induction Regimens: A Study of over Twelve-Thousand Cases in the United States. |
| Q46777295 | Are there real advantages of induction therapy with basiliximab in renal transplantation? |
| Q46873854 | Basiliximab (Simulect) in acute tubular necrosis high-risk kidney transplantation |
| Q46468546 | Basiliximab (Simulect) in renal transplantation with high risk for delayed graft function |
| Q38165224 | Basiliximab: efficacy and safety evaluation in kidney transplantation |
| Q26829578 | Biologics in organ transplantation |
| Q37199764 | Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum |
| Q26830569 | Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets |
| Q37987565 | Current status of immunosuppressive agents for solid organ transplantation in children |
| Q35232066 | Early monitoring of the human polyomavirus BK replication and sequencing analysis in a cohort of adult kidney transplant patients treated with basiliximab |
| Q38802439 | Effectiveness of an Evidence-Based Induction Therapy Protocol Revision in Adult Kidney Transplant Recipients |
| Q41475881 | Effects of interleukin 2 receptor blockers on patient and graft survival in renal-transplanted children. |
| Q39037933 | Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. |
| Q36586891 | Immunosuppressive preconditioning or induction regimens : evidence to date |
| Q36830121 | Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review |
| Q33905617 | Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation |
| Q46613255 | Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference? |
| Q37025883 | Induction therapy in renal transplantation : an overview of current developments |
| Q37815275 | Induction treatment with monoclonal antibodies for heart transplantation |
| Q37156636 | Infectious complications associated with monoclonal antibodies and related small molecules |
| Q36505748 | Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients |
| Q54345873 | Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. |
| Q37771610 | Is there any role for antithymocyte induction in renal transplantation? |
| Q52897493 | Long-term outcome of ATG vs. Basiliximab induction. |
| Q83725172 | Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up |
| Q38141838 | Malignancies after pediatric kidney transplantation: more than PTLD? |
| Q37149427 | Malignancy in kidney transplant recipients |
| Q36088854 | Management and prevention of post-transplant malignancies in kidney transplant recipients |
| Q35690889 | Medical applications of leukocyte surface molecules--the CD molecules |
| Q37982854 | Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose. |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q26826880 | Monoclonal antibody therapy and renal transplantation: focus on adverse effects |
| Q84784155 | New immunosuppressive agents and risk for invasive fungal infections |
| Q38614123 | Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects |
| Q36441441 | Post-transplant lymphoproliferative disease: association with induction therapy? |
| Q36024257 | Reduced progression of cardiac allograft vasculopathy with routine use of induction therapy with basiliximab |
| Q46109510 | Remission of refractory minimal change nephrotic syndrome after basiliximab therapy |
| Q38967258 | Renal transplant immunology in the last 20 years: A revolution towards graft and patient survival improvement |
| Q30316796 | Solid phase-based cross-matching as solution for kidney allograft recipients pretreated with therapeutic antibodies |
| Q41774477 | The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? |
| Q38182645 | The expanding role of therapeutic antibodies |
| Q37877294 | The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus |
| Q43078141 | The role of basiliximab in the evolving renal transplantation immunosuppression protocol |
| Q36328703 | Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections |
Search more.